Baker McKenzie client Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system disorders (CNS), and the Neuraxpharm Group, a leading European specialty pharmaceutical company focused on CNS therapies, announced the completion of a strategic license agreement for the European rights to leriglitazone, a novel, brain penetrant and selective PPAR gamma agonist.

Under the agreement, Minoryx will receive from Neuraxpharm a significant double-digit upfront payment in addition to milestone payments and development funding totaling up to EUR 258 million in the aggregate. Minoryx will also receive material tiered double-digit royalties.

Led by Corporate Partner Randall Sunberg (Princeton / New York), the Baker McKenzie team includes:

Corporate: Devin Muntz (Chicago) and Carlos Martin (Madrid)
Intellectual Property: Maria Dolores Garayalde (Madrid) and Ruben Cano (Madrid)
International Commercial & Trade: Cecilia Pastor (Madrid)
EU Competition & Regulatory: Els Janssens (Belgium), Paul Johnson (Belgium), Bram Hoorelbeke (Belgium) and Beau Maes (Belgium)

Learn more about the deal on Minoryx's website.

This deal is emblematic of the complex cross-border licensing and collaboration matters that Baker McKenzie's Healthcare and Life Sciences lawyers handle on behalf of clients. The team has extensive experience in structuring and negotiating complex collaborations and licensing transactions for clients ranging from biotech start-ups to multinational pharmaceutical companies.

As one of the first law firms to advise life sciences companies on their global expansion 60 years ago, Baker McKenzie's deep knowledge in the industry, honed over the decades, is rooted in the Firm's corporate DNA. The Healthcare and Life Sciences group is one of the largest of any international law firm comprising over 800 lawyers in 45 countries. The Firm has been recognized for their work in the industry, most recently receiving a 2022 Impact Deal of the Year by LMG Life Sciences for their representation of Takeda in its $3.6 billion collaboration with Poseida Therapeutics.

Baker McKenzie is a transactional powerhouse, with more than 2,500 deal lawyers in 45 jurisdictions offering pragmatic counsel in the areas most critical for clients. The Firm excels in complex transactions and cross-border deals – over 65% of the deals are multi-jurisdictional. The teams are global and local, combining money-market sophistication with local excellence.

Explore Our Newsroom